Equities analysts predict that Blueprint Medicines Corp (NASDAQ:BPMC) will report $5.09 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Blueprint Medicines’ earnings, with the highest sales estimate coming in at $8.20 million and the lowest estimate coming in at $1.13 million. Blueprint Medicines posted sales of $7.69 million during the same quarter last year, which suggests a negative year over year growth rate of 33.8%. The business is expected to report its next quarterly earnings results on Thursday, March 8th.

According to Zacks, analysts expect that Blueprint Medicines will report full-year sales of $5.09 million for the current fiscal year, with estimates ranging from $20.92 million to $28.00 million. For the next year, analysts expect that the firm will post sales of $13.41 million per share, with estimates ranging from $4.50 million to $29.40 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Blueprint Medicines.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.06). Blueprint Medicines had a negative net margin of 437.83% and a negative return on equity of 43.11%. The business had revenue of $8.07 million during the quarter, compared to analyst estimates of $5.35 million. During the same period in the prior year, the business posted ($0.62) EPS. The company’s revenue for the quarter was up 31.0% compared to the same quarter last year.

Several research firms recently weighed in on BPMC. Cowen reissued a “buy” rating on shares of Blueprint Medicines in a report on Friday, November 10th. Raymond James Financial set a $82.00 price objective on Blueprint Medicines and gave the company a “buy” rating in a report on Sunday, December 10th. Canaccord Genuity reissued a “buy” rating and set a $80.00 price objective (up previously from $66.00) on shares of Blueprint Medicines in a report on Wednesday, November 1st. Morgan Stanley raised their price objective on Blueprint Medicines from $45.00 to $78.00 and gave the company an “overweight” rating in a report on Monday, October 23rd. Finally, BTIG Research began coverage on Blueprint Medicines in a report on Friday, September 29th. They set a “buy” rating and a $90.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $84.20.

In other Blueprint Medicines news, insider Marion Dorsch sold 18,334 shares of Blueprint Medicines stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $65.45, for a total transaction of $1,199,960.30. Following the transaction, the insider now directly owns 18,334 shares of the company’s stock, valued at approximately $1,199,960.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel Lynch sold 5,000 shares of Blueprint Medicines stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $63.38, for a total value of $316,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 58,334 shares of company stock worth $3,978,160 over the last ninety days. Company insiders own 3.40% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Rockefeller Financial Services Inc. acquired a new position in Blueprint Medicines during the 3rd quarter worth about $160,000. Ameritas Investment Partners Inc. lifted its holdings in Blueprint Medicines by 68.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after buying an additional 1,391 shares during the period. Fred Alger Management Inc. acquired a new position in Blueprint Medicines during the 2nd quarter worth about $203,000. SG Americas Securities LLC lifted its holdings in Blueprint Medicines by 23.3% during the 2nd quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock worth $208,000 after buying an additional 778 shares during the period. Finally, Turner Investments LLC acquired a new position in Blueprint Medicines during the 3rd quarter worth about $209,000. 83.54% of the stock is currently owned by hedge funds and other institutional investors.

Blueprint Medicines (BPMC) traded up $2.14 during midday trading on Wednesday, hitting $75.42. The company had a trading volume of 324,466 shares, compared to its average volume of 371,627. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28. Blueprint Medicines has a 12 month low of $31.35 and a 12 month high of $92.00. The firm has a market cap of $3,230.00 and a P/E ratio of -22.05.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/17/analysts-anticipate-blueprint-medicines-corp-bpmc-will-post-quarterly-sales-of-5-09-million.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.